Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Company news > 2021

Company news, 2021

We made a chemistry game for you. Have fun and enjoy it!
We made a chemistry game for you. Have fun and enjoy it!
We made a chemistry game for you. Have fun and enjoy it!
ChemDiv is now a Discovery Partner with Gwynant Therapeutics and Celyn Therapeutics
ChemDiv is now a Discovery Partner with Gwynant Therapeutics and Celyn Therapeutics
ChemDiv has been selected as a discovery partner with Gwynant Therapeutics and Celyn Therapeutics and starts to work on novel small molecules for oncology targets. See all the details in PR...
ChemDiv at the international symposium on medicinal chemistry
ChemDiv at the international symposium on medicinal chemistry
The XXVI EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2021) will be held virtually, from August 29 to September 2, 2021. We present the following poster: BEYOND BINAR...
Visit our virtual booth at the European Chemical Biology Symposium
Visit our virtual booth at the European Chemical Biology Symposium
The virtual European Chemical Biology Symposium ECBS2021 is co-organised by the EuChemS Division “Chemistry in Life Sciences” (LS-EuChemS) and EU-OPENSCREEN ERIC and brings together scientists fro...
CHEMDIV IS NOW A DISCOVERY PARTNER WITH GWYNANT THERAPEUTICS AND CELYN THERAPEUTICS
CHEMDIV IS NOW A DISCOVERY PARTNER WITH GWYNANT THERAPEUTICS AND CELYN THERAPEUTICS
ChemDiv has been selected as a discovery partner with Gwynant Therapeutics and Celyn Therapeutics and starts to work on novel small molecules for oncology targets.
Our covalent compound library is now available in a ready-to-dock format for BioSolveIT
Our covalent compound library is now available in a ready-to-dock format for BioSolveIT
ChemDiv,Inc.
Methamphetamine use drove surge in heart failure hospitalizations, costs in California
Methamphetamine use drove surge in heart failure hospitalizations, costs in California
DALLAS, July 14, 2021 -- Heart failure hospitalizations and costs related to methamphetamine use jumped sharply over a decade in California, according to new research published today in Circulati...
ESTEVE and KOWA Pharmaceuticals America enter into an Exclusive License and Commercialization Agreement for rights to E-58425 for the potential management of acute pain in the United States
ESTEVE and KOWA Pharmaceuticals America enter into an Exclusive License and Commercialization Agreement for rights to E-58425 for the potential management of acute pain in the United States
BARCELONA, Spain, May 3, 2021 /PRNewswire/ -- Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative ...
Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer
Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer
TOKYO, Japan I March 26, 2021 - Astellas Pharma Inc.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand